Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Otsuka Pharmaceutical
Biotech
Otsuka's kidney disease drug improves UPCR levels in ph. 3 trial
Otsuka’s kidney disease drug hit the primary endpoint of a phase 3 trial by being shown in an interim analysis to have reduced patients’ UPCR levels.
James Waldron
Oct 22, 2024 10:38am
Otsuka pays $800M for Jnana and its clinical-stage PKU drug
Aug 1, 2024 5:55am
Otsuka pays Ionis $65M for European rights to rare disease drug
Dec 19, 2023 10:18am
Otsuka eye disease strategy takes Shape with $1.5B biobucks deal
Sep 8, 2023 8:45am
Otsuka takes on new Mindset for $59M, delving into psychedelics
Sep 1, 2023 10:55am
UK's Astex adds onto Merck cancer collab for $35M upfront
Aug 8, 2023 4:00am
